My Treatment Approach: Translating Evidence to Clinical Practice in Advanced RCC   - Episode 4

STELLAR 304: Zanzalintinib plus nivolumab in non-clear cell RCC

,

Dr. Martin H. Voss provides an analysis of the recent data presented at the American Society of Clinical Oncology (ASCO) 2024 annual meeting, focusing on the phase 3 STELLAR trial, which evaluates the safety and efficacy of the combination therapy Zanzalintinib and nivolumab in patients with non-clear cell renal cell carcinoma.

  1. Please discuss the recent data presented at ASCO 2024 on the phase 3 STELLAR trial
    1. Zanzalintinib (XL092) plus nivolumab in non-clear cell renal cell carcinoma: The randomized phase 3 STELLAR-304 study (Abstract TPS4611)